Clinical trial
MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)
NCT06672237 is registered in ClinicalTrials.gov with Intellia Therapeutics as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- MAGNITUDE-2: A Phase 3, Multinational, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of NTLA-2001 in Participants With Hereditary Transthyretin Amyloidosis With Polyneuropathy (ATTRv-PN)
- Lead sponsor
- Intellia Therapeutics
- Phase
- Phase 3
- Overall status
- Recruiting
- Start date
- November 22, 2024
- Completion date
- August 31, 2028
- Enrollment
- 60 (estimated)
- Sites
- 14
Conditions
As the registry lists them; a condition with its own page is linked.
amyloid neuropathies, amyloid neuropathies, familial, amyloidosis, amyloidosis, familial, amyloidosis, hereditary, genetic disease, inborn, metabolic diseases, metabolism, inborn errors, nerve disorders, nervous system disease, nervous system diseases, neurodegenerative disease, neurodegenerative disease, hereditary, neurodegenerative diseases, neuromuscular disease, neuromuscular diseases, neuromuscular diseases (nmd), peripheral nervous system disease, peripheral nervous system diseases, polyneuropathies